Retour
Également cotée sous
GSK
NYSE
Fourchette du Jour
27,11 €
30,15 €
Fourchette 52 Semaines
15,54 €
31,48 €
Volume
507
Moyenne 50J / 200J
27,21 €
/
22,53 €
Clôture Précédente
26,13 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (627 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 18,3 | 0,3 |
| P/B | 6,4 | 2,9 |
| ROE % | 38,0 | 3,7 |
| Net Margin % | 17,5 | 3,8 |
| Rev Growth 5Y % | -1,1 | 10,0 |
| D/E | 1,1 | 0,2 |
Points Clés
Revenue declined -1,08% annually over 5 years
Earnings grew 121,94% over the past year
ROE of 38,04% indicates high profitability
Net margin of 17,50% shows strong profitability
Generating 5,95B in free cash flow
PEG of 0,10 suggests growth is underpriced
Croissance
Revenue Growth (5Y)
-1,08%
Revenue (1Y)4,10%
Earnings (1Y)121,94%
FCF Growth (3Y)16,01%
Qualité
Return on Equity
38,04%
ROIC15,77%
Net Margin17,50%
Op. Margin21,95%
Sécurité
Debt / Equity
1,08
Current Ratio0,82
Interest Coverage10,23
Valorisation
P/E Ratio
18,30
P/B Ratio6,39
EV/EBITDA16,59
Dividend Yield0,03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 4,10% | Revenue Growth (3Y) | 3,78% |
| Earnings Growth (1Y) | 121,94% | Earnings Growth (3Y) | 7,69% |
| Revenue Growth (5Y) | -1,08% | Earnings Growth (5Y) | 6,85% |
| Profitability | |||
| Revenue (TTM) | 32,66B | Net Income (TTM) | 5,72B |
| ROE | 38,04% | ROA | 9,35% |
| Gross Margin | 72,54% | Operating Margin | 21,95% |
| Net Margin | 17,50% | Free Cash Flow (TTM) | 5,95B |
| ROIC | 15,77% | FCF Growth (3Y) | 16,01% |
| Safety | |||
| Debt / Equity | 1,08 | Current Ratio | 0,82 |
| Interest Coverage | 10,23 | Dividend Yield | 0,03% |
| Valuation | |||
| P/E Ratio | 18,30 | P/B Ratio | 6,39 |
| P/S Ratio | 3,20 | PEG Ratio | 0,10 |
| EV/EBITDA | 16,59 | Dividend Yield | 0,03% |
| Market Cap | 104,58B | Enterprise Value | 118,90B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 32,66B | 31,38B | 30,33B | 29,32B | 34,11B |
| Net Income | 5,72B | 2,58B | 4,93B | 14,96B | 4,39B |
| EPS (Diluted) | 1,39 | 0,62 | 1,20 | 3,66 | 1,35 |
| Gross Profit | 23,69B | 22,33B | 21,76B | 19,77B | 22,51B |
| Operating Income | 7,17B | 4,02B | 6,75B | 6,43B | 6,20B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 61,11B | 59,46B | 59,01B | 60,15B | 79,10B |
| Total Liabilities | 45,09B | 46,38B | 46,21B | 50,05B | 57,76B |
| Shareholders' Equity | 16,37B | 13,67B | 13,35B | 10,60B | 15,06B |
| Total Debt | 17,72B | 16,99B | 18,02B | 20,99B | 24,17B |
| Cash & Equivalents | 3,40B | 3,69B | 2,94B | 3,72B | 4,27B |
| Current Assets | 17,51B | 17,00B | 18,64B | 20,77B | 18,67B |
| Current Liabilities | 21,39B | 21,70B | 21,07B | 22,81B | 23,67B |